BR112022027101A2 - Anticorpos multiespecíficos que se ligam a bcma - Google Patents
Anticorpos multiespecíficos que se ligam a bcmaInfo
- Publication number
- BR112022027101A2 BR112022027101A2 BR112022027101A BR112022027101A BR112022027101A2 BR 112022027101 A2 BR112022027101 A2 BR 112022027101A2 BR 112022027101 A BR112022027101 A BR 112022027101A BR 112022027101 A BR112022027101 A BR 112022027101A BR 112022027101 A2 BR112022027101 A2 BR 112022027101A2
- Authority
- BR
- Brazil
- Prior art keywords
- bcma
- bind
- antibodies
- specific antibodies
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046477P | 2020-06-30 | 2020-06-30 | |
| PCT/US2021/039961 WO2022006316A1 (en) | 2020-06-30 | 2021-06-30 | Multi-specific antibodies binding to bcma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022027101A2 true BR112022027101A2 (pt) | 2023-03-14 |
Family
ID=77127069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022027101A BR112022027101A2 (pt) | 2020-06-30 | 2021-06-30 | Anticorpos multiespecíficos que se ligam a bcma |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230257473A1 (https=) |
| EP (1) | EP4171750A1 (https=) |
| JP (1) | JP2023532129A (https=) |
| KR (1) | KR20230038211A (https=) |
| CN (1) | CN116472049A (https=) |
| AU (1) | AU2021300179A1 (https=) |
| BR (1) | BR112022027101A2 (https=) |
| CA (1) | CA3189297A1 (https=) |
| CL (1) | CL2022003754A1 (https=) |
| CO (1) | CO2023000808A2 (https=) |
| CR (2) | CR20220656A (https=) |
| IL (1) | IL299027A (https=) |
| JO (1) | JOP20220357A1 (https=) |
| MX (1) | MX2022016342A (https=) |
| PE (1) | PE20230464A1 (https=) |
| WO (1) | WO2022006316A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322083A (en) | 2016-08-24 | 2025-09-01 | Teneobio Inc | Non-human transgenic animals that produce modified heavy chain antibodies only |
| IL317134A (en) | 2016-12-21 | 2025-01-01 | Teneobio Inc | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation |
| CN110945026B (zh) | 2017-06-20 | 2024-03-19 | 特纳奥尼股份有限公司 | 仅有重链的抗bcma抗体 |
| CN111683966B (zh) | 2017-12-22 | 2023-07-11 | 特尼奥生物股份有限公司 | 与cd22结合的重链抗体 |
| WO2020206330A1 (en) | 2019-04-05 | 2020-10-08 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
| CR20210622A (es) | 2019-06-14 | 2022-06-27 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
| EP4611163A4 (en) | 2022-12-02 | 2025-11-26 | Lg Energy Solution Ltd | BATTERY BLOCK AND ITS MANUFACTURING PROCESS |
| WO2025010477A1 (en) * | 2023-07-13 | 2025-01-16 | Telix Pharmaceuticals (Innovations) Pty Ltd | Humanised antibodies and uses thereof |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO2001024812A1 (en) | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| WO2002066516A2 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| EP1585768A2 (en) | 2003-01-23 | 2005-10-19 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| KR101151957B1 (ko) | 2004-07-22 | 2012-06-01 | 로저 킹돈 크레이그 | 결합 분자 |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| CA2720682A1 (en) | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| MX341884B (es) | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| DE102010039018B4 (de) * | 2010-08-06 | 2013-02-28 | Technische Universität Dresden | Anti-La Antikörper und ihre Anwendung zum Immunotargeting |
| EP3974453A3 (en) | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| US20130101599A1 (en) | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| WO2014122143A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | Method for the selection of antibodies against bcma |
| EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| MX2018002043A (es) | 2015-08-17 | 2018-07-06 | Janssen Pharmaceutica Nv | ANTICUERPOS ANTI-BCMA, MOLíCULAS DE UNIíN A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS. |
| KR20250175345A (ko) | 2016-06-21 | 2025-12-16 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| IL322083A (en) | 2016-08-24 | 2025-09-01 | Teneobio Inc | Non-human transgenic animals that produce modified heavy chain antibodies only |
| PE20241349A1 (es) | 2016-09-14 | 2024-07-03 | Teneobio Inc | Anticuerpos de union a cd3 |
| WO2018224660A1 (en) * | 2017-06-09 | 2018-12-13 | Armin Ehninger | Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders |
| KR20250007003A (ko) * | 2017-06-20 | 2025-01-13 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| CN110945026B (zh) * | 2017-06-20 | 2024-03-19 | 特纳奥尼股份有限公司 | 仅有重链的抗bcma抗体 |
| WO2019000223A1 (en) * | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF |
| ES2928296T3 (es) | 2017-06-30 | 2022-11-16 | Us Health | Receptores de antígenos quiméricos anti-antígenos de maduración de linfocitos B con dominios humanos |
| EP3581200A1 (en) * | 2018-06-13 | 2019-12-18 | GEMoaB Monoclonals GmbH | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
-
2021
- 2021-06-30 CN CN202180052312.5A patent/CN116472049A/zh active Pending
- 2021-06-30 MX MX2022016342A patent/MX2022016342A/es unknown
- 2021-06-30 PE PE2022003030A patent/PE20230464A1/es unknown
- 2021-06-30 EP EP21748714.9A patent/EP4171750A1/en active Pending
- 2021-06-30 KR KR1020237003291A patent/KR20230038211A/ko active Pending
- 2021-06-30 CR CR20220656A patent/CR20220656A/es unknown
- 2021-06-30 WO PCT/US2021/039961 patent/WO2022006316A1/en not_active Ceased
- 2021-06-30 US US18/002,472 patent/US20230257473A1/en active Pending
- 2021-06-30 IL IL299027A patent/IL299027A/en unknown
- 2021-06-30 CA CA3189297A patent/CA3189297A1/en active Pending
- 2021-06-30 JP JP2022581401A patent/JP2023532129A/ja active Pending
- 2021-06-30 BR BR112022027101A patent/BR112022027101A2/pt unknown
- 2021-06-30 AU AU2021300179A patent/AU2021300179A1/en active Pending
- 2021-06-30 CR CR20250505A patent/CR20250505A/es unknown
-
2022
- 2022-12-26 CL CL2022003754A patent/CL2022003754A1/es unknown
- 2022-12-29 JO JOJO/P/2022/0357A patent/JOP20220357A1/ar unknown
-
2023
- 2023-01-25 CO CONC2023/0000808A patent/CO2023000808A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20250505A (es) | 2026-01-13 |
| US20230257473A1 (en) | 2023-08-17 |
| KR20230038211A (ko) | 2023-03-17 |
| WO2022006316A1 (en) | 2022-01-06 |
| MX2022016342A (es) | 2023-01-24 |
| AU2021300179A1 (en) | 2023-02-02 |
| EP4171750A1 (en) | 2023-05-03 |
| CO2023000808A2 (es) | 2023-02-16 |
| CN116472049A (zh) | 2023-07-21 |
| JOP20220357A1 (ar) | 2022-12-29 |
| CL2022003754A1 (es) | 2023-07-07 |
| CA3189297A1 (en) | 2022-01-06 |
| JP2023532129A (ja) | 2023-07-26 |
| IL299027A (en) | 2023-02-01 |
| CR20220656A (es) | 2023-03-01 |
| PE20230464A1 (es) | 2023-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022027101A2 (pt) | Anticorpos multiespecíficos que se ligam a bcma | |
| BR112019012354A2 (pt) | anticorpos apenas de cadeia pesada anti-bcma | |
| BR112021019334A2 (pt) | Anticorpos de cadeia pesada que se ligam ao psma | |
| CO2022018811A2 (es) | Inhibidores de la proteína kras g12c y usos de estos | |
| CO2021003036A2 (es) | Compuestos de anillo fusionado | |
| DOP2022000229A (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| MX2020008075A (es) | Anticuerpos anti-ctla4 y métodos para elaborarlos y usarlos. | |
| CO2024005925A2 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| ECSP22083174A (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| CL2021003343A1 (es) | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3. | |
| MX380122B (es) | Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas. | |
| CO2023006684A2 (es) | Anticuerpos contra sars-cov-2 y usos de los mismos | |
| BR112023020450A2 (pt) | Anticorpos anti-cd19 e estruturas car-t | |
| MX2024002391A (es) | Inhibidores de indolina de kif18a. | |
| BR112022011824A2 (pt) | Anticorpos de cadeia pesada que se ligam a cd38 | |
| CL2023003073A1 (es) | Anticuerpos anti-cd20 y estructuras car-t | |
| MX2023009882A (es) | Anticuerpos anti-muc1-c y estructuras car-t. | |
| CO2022016754A2 (es) | Moléculas de fijación para el tratamiento de cáncer | |
| CL2023001220A1 (es) | Inhibidores de interleucina-17 | |
| CL2025003369A1 (es) | Inhibidores de egfr para el tratamiento de enfermedades | |
| MX2023000198A (es) | Inhibidores de atr y usos de estos. | |
| BR112022004809A2 (pt) | Compostos 2-amino-s6-tiopurina substituídos como inibidores da proteína enpp1 | |
| AR122120A1 (es) | Moléculas de fijación para el tratamiento de cáncer | |
| BR112019000603A2 (pt) | composto, composição farmacêutica, método para o tratamento de doenças e uso do composto |